STOCKS TELEGRAPH

Tag: ATOS stock price

  • Atossa Therapeutics Inc. (ATOS) stock surged in the premarket trading session; here’s why

    Atossa Therapeutics Inc. (ATOS) stock surged in the premarket trading session; here’s why

    In the premarket trading session, at last check, Atossa Therapeutics Inc. (ATOS) stock had surged by 2.55% to $6.04. ATOS’s stock previously closed the session gaining 10.09% to $5.89. The ATOS stock volume traded 14.72 million shares. In the past week, ATOS shares have moved up by 27.49%. In the past three and six months, the ATOS stock has jumped up by 135.60%, and 584.72% respectively. Furthermore, Atossa therapeutics Inc. is currently valued in the market at $711.65 million and has 120.82 million outstanding shares.

    Here’s what you need to know about Atossa Therapeutics Inc.

    Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the developing and designing of unique innovative treatments and medicines for the unmet needs of the health market. The company specifically focuses on the platform of development and design of medicines for the areas of oncology and infectious disease.

    The company has created programs to fight breast cancers, improve lung functions and has therapy programs as well for the treatment of cancers. The lead candidate program is known as Endoxifen for breast cancer treatment which is in Phase II of clinical trials and is a metabolite of tamoxifen. AT-H201 and AT-301 are proprietary drugs used for the treatment and recovery of lung function in COVID19 patients. ATOS stock also participates and supports research for treatments like potential treatment of breast cancer through cytokine-coated nanoparticles in partnership with Dana-Farber Cancer Institute Inc. Furthermore, the company was previously known as Atossa Genetics Inc up till January 2020 and is founded in 2008. The Atossa headquarters is in Seattle Washington.

    How has Atossa’s operations been doing lately?

    The month of June has been very progressive and successful for ATOS stock and Atossa’s clinical study operations. On 16th June 2021, the company was announced to be part of the Russell 2000 and Russell 3000 Indexes. Atossa is primarily focusing on Breast cancer and COVID19-related treatments. There is a preliminary list of additions that were posted on 4th and 14th June 2021, informing that the official integration will be concluded on 2021 Russell Indexes’ annual reconstitution. The implementation will be effective after US market opens on June 28, 2021.

    On 11th June 2021, ATOS stock received approval from the Swedish Medical Product Agency (MPA) which encourages the initiation of Endoxifen’s second phase clinical trial study. Endoxifen will be used for the treatment and reduction of mammographic breast density (MBD) which is affecting more than 10 million women in the US and scattered across the globe. Increased mammographic breast density results in the difficulty of detecting cancer and increases the development of breast cancer risk.

    Furthermore, Atossa Therapeutics announced the final data of the phase 2 study of oral Endoxifen. This study was used to test the efficacy and safety of the administration of the dose between the time of diagnosis of breast cancer and surgery. The primary endpoint met result showed Ki-67 reduction by an average of 25.6% and has shown clinically meaningful results because these statistics according to to other studies showed a result of improved survival rate.

  • Atossa Therapeutics, Inc. (ATOS) stock up over 6%: Let’s find out why.

    Atossa Therapeutics, Inc. (ATOS) stock up over 6%: Let’s find out why.

    Shares of Atossa Therapeutics, Inc. (ATOS) stock continued the uptrend in today’s market on May 3, 2021, after gaining 0.43% at the previous closing. ATOS stock price saw a surge of 6.01% a share to reach $2.47 a share as of this writing. Atossa CEO Dr. Steven Quay’s participation in a panel discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021, is the only recent news announced by the Atossa stock on April 30, 2021. Let’s discuss more of it.

    What’s happening?

    Atossa Therapeutics, Inc being a pharmaceutical company engages in the discovery and development of medicines related to oncology and infectious diseases. Individuals are eyeing the upcoming panel discussion this week which will last for three days. Many speakers of reputed venture investment funds will attend the conference.

    Previous Development:

    ATOS stock on April 08, 2021, did announce the beginning of treatment of ovarian cancer patient with Atossa’s proprietary oral Endoxifen following the approval of expanded access by the U.S.A Food & Drug Administration for Endoxifen in the “Safe to Proceed” letter. Dr. Barbara Goff, Surgeon-in-Chief treated the patient at the University of Washington Medical Center. The use of Enodxifen was restricted only to that patient and the initial testing showed exceptional results of tumor response after the combination of Endoxifen and alpelisib.

    Financial View of ATOS stock:

    • ATOS stock announced its financial results for the fiscal year 2020 according to which Atossa stock had no source of sustainable revenue and no associated cost of revenue at the end of the year 2020.
    • ATOS stock reported operating expenses of $14,607,000 for the year 2020 which represents a 15% decrease as compared to the operating expenses of 2019.
    • Research and development expenses for ATOS stock were reduced by 1% as compared to 2019 to drop at $6,608,000.Stock-based compensation of $2,214,000 was mainly responsible for this decrease.
    • General and administrative expenses for ATOS stock were totaled $7,999,000 for 2020 representing a decrease of 25% as compared to 2019. The main reason for this decrease was Stock-based compensation of roughly $3,610,000.
    • ATOS stock reported cash, cash equivalents, and restricted cash of $39.7 million at the end of the year 2020.

    Conclusion:

    Things are going well for ATOS stock as far as market sentiment is concerned and the upcoming conference discussed above will further decide the future of the ATOS stock.